Innovation by Pharma Companies to Boost ADHD Drugs Industry

ADHD is a neurodevelopmental/ neurobehavioral brain disorder characterized by impairing and pervasive symptoms of hyperactivity, impulsivity, and inattention. Centers for Disease Control and Prevention (CDC) has defined ‘neurobehavioral’ as the way brain disturbs behavior, learning, and emotion. Scientists at the National Institute of Mental Health (NIMH) state that the factors disturbing mental illness comprise of brain injuries, drugs used during pregnancy, low birth weight, and contact with environmental contaminants such as lead, at a young age. 

High Consumer Demand to Boost Market

The major drug type variants in the market include stimulant and non-stimulant drugs. Stimulant drugs further comprise Methylphenidate, Amphetamine, Dexmethylphenidate, and Lisdexamfetamine. Non-stimulant drugs comprise Guanfacine, Atomoxetine, Bupropion, and Clonidine. 

The stimulant drug type segment accounted for the largest share in the market and will continue its dominance over the forthcoming period. The key factors that could be attributed to the growth include high demand for these drugs owing to their effectiveness in treating symptoms of this disorder. In addition, government support and ongoing clinical trials for the use of stimulants in the treatment of mental health disorders will spur the demand in the forecast period.  

In April 2016, Tris Pharma, Inc. declared the introduction of its FDA-approved ADHD tablet Dyanavel XR, that is used to treat patients 6 years and above.

Non-stimulants are anticipated to show the fastest development rate in the years to come owing to their long-term result related to stimulants. Additionally, the growing number of market players have been capitalizing on the growth of non-stimulant drugs in the market, which will likely drive the non-stimulants drug segment in the forecast period. 

Market Insights: 

In December 2015, U.S. Food and Drug Administration (FDA) gave approval to Pfizer for Quillichew ER, a chewable capsule for therapy of ADHD in patients over the age of six. This is presented in 40mg, 30mg, and 20mg formulations. Additionally, in February 2018, Lupin launched a generic form of Kapvay in the U.S, which extended its product line for the treatment of this syndrome.

Leading players operating in the attention deficit hyperactivity disorder (ADHD) market include Pfizer; Eli Lily and Company; Lupin; Johnson & Johnson Services, LLC; Shire; Prude Pharma L.P.; NEOS Therapeutics Inc; and Mallinckrodt. These key manufacturers also emphasize on numerous other business strategies, such as product developments, partnerships, technical collaborations, agreements, and capacity expansions to support their market place.